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A B ST R AC T 
 
A R T IC LE D A T A 
Granulocytic sarcoma is a rare type of tumor composed of extramedullary 
immature cells. The breast location is very rare; it accounts for less than 
8% of cases. The present study reports the case of a 36-year-old female 
with a medical history of myelodysplastic syndrome. She was referred 
because of a lump in the left breast. We have diagnosed a case of 
granulocytic sarcoma of the breast by core biopsy. Histology and 
immunohistochemistry showed hypercellular smears with immature 
myeloid cells. The blast cells were myeloperoxidase positive.  
The patient underwent a lumpectomy. Five months later, she developed a 
contralateral recurrence, treated by lumpectomy and radiotherapy. Three 
years later, she developed a recurrence in the left knee. 
We report this case for its rarity and as a note of caution to a physician to 
consider myeloid sarcoma in the differential diagnosis of a breast lump, to 
provide the correct diagnosis and avoid incorrect treatment of a curable 
disease. 
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Introduction  
Granulocytic sarcoma of the breast (GS), also known 
as myeloid or chloroma sarcoma, is a rare extramedullary 
manifestation of acute myeloid leukemia (AML) and 
myelodysplastic syndrome (MDS). It accounts for less 
than 8% of cases. It was first described by Burns in 1811. 
It is characterized by an unusual type of tumor composed 
of immature cells outside the bone marrow. The tumor 
can arise de-novo or in association with hematological 
malignancies [1-5]. Here we present an isolated 
recurrence of GS in the breast, with treatment outcomes.  
Case presentation 
A 36-year-old woman presented with the clinical 
history of MDS occurring four years earlier. She had 
undergone allogeneic bone marrow transplantation. The 
patient was free of disease, but she was subsequently 
undergoing therapy for graft-versus-host disease reaction. 
She was referred to our institute with complaints of a 
painful mass in the left breast that had been apparent for 
one month. On physical exam, we found a well-defined 
mass located in the upper outer quadrant of the left breast, 
measuring 40 mm, without skin modification.  
The complete blood count and peripheral blood 
examination were normal. Mammography showed an 
asymmetric opacity in the periareolar area without 
microcalcifications. Breast ultrasound showed a 
heterogenous well-circumscribed mass in the left breast 
measuring 40 mm without posterior acoustic shadowing 
and internal vascularity (Figure 1). 
A core biopsy of the mass was performed. Histology 
and immunohistochemistry revealed hypercellular smears 
with immature myeloid cells few neutrophils and many 
large round cells with the high nuclear-cytoplasmic ratio, 
prominent nucleoli, and a moderate amount of granular 
cytoplasm (Figure 2). The blast cells were positive for 
myeloperoxidase enzyme (MPO), vimentin, and CD117 
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and negative for Pan B, and Pan T (Figure 3). The 
diagnostic was a breast relapse for her MDS, known as 
GS of the breast. 
 
Figure 1. (A) hyperdense opacity in the periareolar area 
without microcalcifications on mammography (yellow 
asterisk); (B) a heterogenous well-circumscribed mass, 
measured 40 mm in the left breast without posterior 
acoustic on ultrasound.  
The patient underwent a left breast lumpectomy.  In 
the macroscopic examination, we found a grayish mass 
measuring 50 mm, and the margins were free of disease. 
Radiotherapy was proposed for the patient, but she failed 
to follow up. Five months later, she consulted for 
contralateral breast mass. Upon examination we found a 
well-defined mass, measuring 15 mm in the right 
submammary fold. She underwent a local excision. The 
histologic findings showed a GS of the right breast, with 
free margins.  
 
Figure 2. Progressive magnification in Hematoxylin-
eosin staining: (A) ×5; (B) × 10; (C) ×20; (D) ×40; 
showing hypercellular smears with immature myeloid 
cells few neutrophils, megakaryocytes and many large 
round cells with the high nuclear-cytoplasmic ratio. 
The patient received adjuvant radiotherapy for the left 
breast, and contact radiotherapy for the right breast. The 
total dose was 36 Gy for both breasts.  Three years later 
she presented an isolated recurrence in her left knee. The 
clinical exam showed a hard mass, measuring 40 mm. 
The MRI showed a suspected mass measuring 88×32 mm 
with cribriform appearance, infiltrating the ligament and 
the tendon of the left knee (Figure 4). The core biopsy and 
histologic findings confirmed the recurrence of her 
anterior GS. The multidisciplinary committee outlined 
surgery, but the patient refused the operation. 
Chemotherapy has been challenged due to localized 
disease. The patient was then lost again to follow up, 
though in good general condition when released.  
 
Figure 3. Immunohistochemistry features, (A) 
Myeloperoxidase; (B) vimentin; (C) and (D) CD117. 
Magnification: 20×.  
 
Figure 4. MRI sequence T1-weighted with Gadolinium 
showed a suspected mass measuring 88×32 mm with 
cribriform appearance, infiltrating the ligament and the 
tendon of the left knee. 
Discussions 
GS of the breast most commonly occurs in patients 
with previously diagnosed AML or MDS. The breast is an 
uncommon site for presentation of this tumor.  It is 
characterized by the formation of tumors containing 
immature myeloid cells [1, 2, 5-7]. GS can arise in any 
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part of the human body, but bones, lymph nodes, soft 
tissues, and skin are among the most common sites of 
presentation other than the urogenital tract [1, 4, 6]. 
The rarity of breast GS makes the diagnosis difficult, 
often being misdiagnosed as lymphoma, sarcoma, or 
breast carcinoma, especially in the absence of bone 
marrow invasion.  In this case, the patient had a medical 
history of the hematological disease, even though with 
complete remission [4, 7, 8]. 
The clinical manifestations of the GS of the breast 
are not specific. It often manifests as a palpable mass 
that can be either painless or painful. Other symptoms 
can be found such as skin involvement and axillary 
lymph node, although nipple retraction or discharge or 
inversion is not common [1, 4, 7]. 
Due to their rarity of the condition, radiological 
findings are variable. It is difficult to differentiate GS   
from benign lesions or other malignant lesions. The 
ultrasonography showed a regular or micolobulated 
mass with well-defined margins, irregularly shaped, 
heterogeneous or hypoechoic with visible posterior 
acoustic shadows. Sometimes, it appears with spiculated 
or microlobulated margins [5, 7].  
On the mammography, the lesions can have regular 
or irregular limits usually without microcalcifications (2, 
8). Sometimes MRI is used to eliminate diagnostic 
errors, but results are often indistinguishable from 
benign and malignant lesions; GS appears on T2 as 
hyperintense, heterogeneous, well-defined [4, 7]. The 
diagnosis is confirmed only by core biopsy and 
histological examination. 
Lumpectomy combined with systemic chemotherapy 
results in a good outcome.  Some studies had 
demonstrated that the overall survival was longer in 
patients treated by chemotherapy compared with those 
who did not receive chemotherapy [5-7]. However, 
because of the limited number of GS cases in the 
literature, therapeutic approaches remain controversial.  
The pillar of treatment is systemic chemotherapy 
with regimens normally utilized for AML [1, 8]. Several 
studies and reviews have featured the significance of 
early systemic therapy in order to accomplish a long, 
disease-free survival and to avoid AML development or 
relapse [9–13].  
There is an absence of clear indication for 
combination chemotherapy with radiotherapy since 
survival rates appear to be equal, despite the fact that it 
may be a valuable device for symptomatic relief or in 
refractory disease. In addition, several retrospective 
studies have shown a high rate of AML development in 
patients with isolated GS experiencing radiotherapy or 
surgery alone. Our case was unique due to the unusual 
treatment management; we performed lumpectomy and 
radiotherapy without chemotherapy with good 
outcomes.   
There is no clear consensus whether or not bone 
marrow transplantation has an effect even though recent 
studies have shown a significant survival benefit [10, 11, 
13]. Finally, promising targeted therapies currently in 
trial for AML, such as FLT3 inhibitors, farnesyl-
transferase inhibitors and histone deacetylase inhibitors, 
might be an effective option against GS [10]. 
Histopathology and the immunohistochemistry 
confirm the diagnostic. Macroscopically the tumors had 
a green color, due to the MPO present in the myeloid 
cells [3, 14]. Histological examination usually shows the 
presence of the myeloblasts, these cells appeared pale on 
hematoxylin and eosin stain, the nucleus was irregular 
with finely granular chromatin with scanty cytoplasm 
[3]. 
Immunohistochemical usually confirms the 
diagnosis. There is a large array of cytogenetic tests and 
flow cytometry to distinguish GS from lymphoma [6, 7]. 
The tumor is often positive for MPO, CD117, CD99, 
CD68, lysozyme, and nucleophosmin. The most frequent 
cytogenetic and biochemical abnormalities carry t(8; 
21), inv [14], and cytoplasmic expression of NPM and 
FLT3-ITD [10].  
Prognosis depends on some factors such as 
cytogenetic profiles and age of onset. Some studies have 
shown that the prognosis in isolated disease is better 
than GS without medullary involvement [1, 5]. 
Highlights  
Extramedullary manifestation of acute myeloid 
leukemia are various, the breast mass in this context is 
very rare, the aim of this report to keep on mind the 
diagnosis of granulocytic sarcoma even the patient was in 
complete remission.  
Conclusions 
GS of the breast is a rare manifestation of MDS. The 
diagnosis is thus difficult to establish. GS can mimic other 
neoplasms like lymphoma and breast carcinoma, so it can 
be easily misdiagnosed without the immunohistochemistry 
which uses a vast panel of markers. The management of 
this disease remains unclear; some studies have concluded 
that lumpectomy combined with systemic chemotherapy 
may give good results. 
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